Amgen’s Solid Dividend Role in SCHD: Growth, Risks, & Yield Insights
Amgen’s steady dividends and strong cash flow keep it a key driver in Schwab’s SCHD ETF, yet patent cliffs and biosimilar pressure could erode long‑term returns.
5 minutes to read
Top News
Market Overview
Top Sector News (Consumer Discretionary)
